Intra-Cellular Therapies, Inc. (ITCI)

業務介紹

內細胞治療公司(Intra-Cellular Therapies, Inc.)是一家生物製藥公司,在美國開發用於治療神經精神疾病和神經系統疾病的新型藥物,目標是中樞神經系統內的細胞內信號機制。該公司提供CAPLYTA用於治療成人精神分裂症。該公司還在開發lumateperone,正處於III期臨床試驗階段,用於治療雙相性抑鬱症,以及治療自閉症譜系障礙和其他神經精神疾病相關的睡眠障礙。此外,該公司正在開發Lenrispodun (ITI-214)用於治療帕金森病和心力衰竭;ITI-1284-ODT-SL用於治療神經精神疾病和老年癡呆症的行為障礙;以及ITI-333用於治療物質使用障礙、疼痛和精神共病,包括抑鬱和焦慮。內細胞治療公司成立於2002年,總部位於紐約。



Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

公司網址

https://www.intracellulartherapies.com